Sebastian Burgis

Sebastian Burgis primarily focuses on capital markets transactions and corporate matters, advising clients in a variety of industries. In recognition of his work, Mr. Burgis was named one of Best Lawyers’ 2025 Ones To Watch. His recent significant representations include:

• MorphoSys AG in:
  • its pending €2.7 billion sale to, and public takeover by, Novartis and the simultaneous disposition of the worldwide marketing rights of its antibody drug Monjuvi to Incyte Corporation
  • connection with a cash capital increase with gross proceeds of approximately €102.7 million and the issuance of a US$300 million development funding bond
• Armira in its €30 million anchor investment as part of a €60 million private placement of new shares in tonies SE
• Silver Lake in its strategic partnership and investment in German publicly listed company Software AG via the purchase of €344 million aggregate principal amount of subordinated unsecured convertible notes. This is the first PIPE by any U.S. technology investment firm in a German public company
• Berenberg as sole global coordinator and joint bookrunner and Stifel as additional joint bookrunner in connection with a capital increase of Pacifico Renewables Yield AG
• the joint bookrunners, including Deutsche Bank and J.P. Morgan, in the €842 million private placement of ordinary bearer shares and listing on the Frankfurt Stock Exchange of ABOUT YOU Holding AG
• SIGNA Sports United GmbH in connection with its US$3.3 billion initial public offering on the New York Stock Exchange as a result of the de-SPAC merger with Yucaipa Acquisition Corporation. The merger also included the acquisition of WiggleCRC Group

Prior to joining Skadden, Mr. Burgis gained experience as a law clerk in the Frankfurt and Brussels offices of other international law firms.